Ovid Therapeutics (OVID) Change in Accured Expenses (2016 - 2026)
Ovid Therapeutics' (OVID) quarterly Change in Accured Expenses came in at -$1.4 million in Q1 2026, down 140100.0% YoY from N/an in Q1 2025, and down 168.32% on a QoQ basis from $2.1 million in Q4 2025.
Ovid Therapeutics (OVID) Change in Accured Expenses (2016 - 2026) Analysis & Trends
Ovid Therapeutics (OVID) has 11 years of Change in Accured Expenses data on file, last reported at -$1.4 million in Q1 2026.
- Quarterly Change in Accured Expenses fell 140100.0% year-over-year to -$1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.5 million (down 226.75% YoY) and the FY2025 annual result came in at -$1.1 million, down 98.88% from the prior year.
- Change in Accured Expenses declined to -$1.4 million in Q1 2026, from $2.1 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $4.1 million in Q2 2024 to a low of -$3.4 million in Q2 2022.
- A 5-year average of -$244270.9 and a median of -$1000.0 in 2025 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2025 — Change in Accured Expenses jumped 229.55% — and 2026, when it sank 140100.0%.
- Tracing OVID's Change in Accured Expenses over 5 years: stood at -$1.2 million in 2022, then jumped by 125.36% to $303000.0 in 2023, then plunged by 622.77% to -$1.6 million in 2024, then jumped by 229.55% to $2.1 million in 2025, then slumped by 168.32% to -$1.4 million in 2026.
- The last three Change in Accured Expenses figures came in at -$1.4 million (Q1 2026), $2.1 million (Q4 2025), and $27000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Ovid Therapeutics | 385.37 Mn | 229.84 Mn | - | -1.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.40 Mn |
| Mar 31, 2026 | -1.40 Mn |
| Dec 31, 2025 | 2.05 Mn |
| Dec 31, 2025 | 2.05 Mn |
| Sep 30, 2025 | 27,000.00 |
| Sep 30, 2025 | 27,000.00 |
| Jun 30, 2025 | -3.15 Mn |
| Jun 30, 2025 | -3.15 Mn |
| Mar 31, 2025 | -1,000.00 |
| Mar 31, 2025 | -1,000.00 |
| Dec 31, 2024 | -1.58 Mn |
| Dec 31, 2024 | -1.58 Mn |
| Sep 30, 2024 | -535,000.00 |
| Sep 30, 2024 | -535,000.00 |
| Jun 30, 2024 | 4.07 Mn |
| Jun 30, 2024 | 4.07 Mn |
| Mar 31, 2024 | -2.49 Mn |
| Mar 31, 2024 | -2.49 Mn |
| Dec 31, 2023 | 303,000.00 |
| Dec 31, 2023 | 303,000.00 |